NCT03004183: SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC

NCT03004183
Breast Cancer Type: Triple Negative
Hormone Mutations:
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Immunotherapy, Therapeutic Antibody, Radiation Therapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with tumors for which SBRT is not considered appropriate standard therapy (e.g. target lesions less than 1 cm in diameter); Patents with known active unstable central nervous system metastases and/or carcinomatous meningitis that require treatment
https://ClinicalTrials.gov/show/NCT03004183

Comments are closed.

Up ↑